Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
Antibodies against programmed cell death protein-1 or its ligand (PD-(L)1) are a standard of care in melanoma; however, this treatment may cause immune-related adverse events. The aim of this study was to evaluate the immune-related thyroid adverse events (irTAEs) during anti-PD-1 therapy and analyze their influence on the overall survival rates in melanoma. We included 249 patients with metastatic melanoma treated in our institution between 2014 and 2021; the median age was 62 years (range: 17-90); 58% were males, and 37% of patients had the BRAF mutation. We included patients with a normal TSH at baseline and followed up with measurement of TSH levels during immunotherapy. In our group, 95 patients had a TSH outside the normal range: 63 not clinically significant and 32 with clinical symptoms of hypothyroidism. The 3-year overall survival rate was related to the irTAEs of clinical hypothyroidism, abnormal clinically not significant TSH, and euthyreosis at 56%, 43%, and 32%, respectively (p = 0.002). After adjusting the Cox model for potential confounding variables, clinically significant hypothyroidism was an independent prognostic factor with HR 0.51 (95% CI 0.29-0.87). In conclusion, the patients who developed clinically significant hypothyroidism requiring replacement therapy with L-thyroxin were the group who benefitted most from anti-PD-1 treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2022), 5 vom: 28. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dawidowska, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Endocrinopathies |
|---|
| Anmerkungen: |
Date Revised 16.03.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers14051248 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337984050 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337984050 | ||
| 003 | DE-627 | ||
| 005 | 20231225235642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14051248 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM337984050 | ||
| 035 | |a (NLM)35267557 | ||
| 035 | |a (PII)1248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dawidowska, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Antibodies against programmed cell death protein-1 or its ligand (PD-(L)1) are a standard of care in melanoma; however, this treatment may cause immune-related adverse events. The aim of this study was to evaluate the immune-related thyroid adverse events (irTAEs) during anti-PD-1 therapy and analyze their influence on the overall survival rates in melanoma. We included 249 patients with metastatic melanoma treated in our institution between 2014 and 2021; the median age was 62 years (range: 17-90); 58% were males, and 37% of patients had the BRAF mutation. We included patients with a normal TSH at baseline and followed up with measurement of TSH levels during immunotherapy. In our group, 95 patients had a TSH outside the normal range: 63 not clinically significant and 32 with clinical symptoms of hypothyroidism. The 3-year overall survival rate was related to the irTAEs of clinical hypothyroidism, abnormal clinically not significant TSH, and euthyreosis at 56%, 43%, and 32%, respectively (p = 0.002). After adjusting the Cox model for potential confounding variables, clinically significant hypothyroidism was an independent prognostic factor with HR 0.51 (95% CI 0.29-0.87). In conclusion, the patients who developed clinically significant hypothyroidism requiring replacement therapy with L-thyroxin were the group who benefitted most from anti-PD-1 treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a endocrinopathies | |
| 650 | 4 | |a immune-related adverse event | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Jagodzinska-Mucha, Paulina |e verfasserin |4 aut | |
| 700 | 1 | |a Koseła-Paterczyk, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Jaczewska, Sylwia |e verfasserin |4 aut | |
| 700 | 1 | |a Sobczuk, Paweł |e verfasserin |4 aut | |
| 700 | 1 | |a Chelstowska, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Kowalska, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Badziak-Sterczewska, Honorata |e verfasserin |4 aut | |
| 700 | 1 | |a Poleszczuk, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Rutkowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Lugowska, Iwona |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 14(2022), 5 vom: 28. Feb. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:5 |g day:28 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers14051248 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 5 |b 28 |c 02 | ||